menu
    • menu

    Company profile for Inmagene Biopharmaceuticals

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    With subsidiaries in Shanghai, Hangzhou and Beijing, Inmagene strives to be the leading company in immunology-related therapeutic areas in China. The company has been founded by a group of entrepreneurs, including clinicians, scientists and former venture capitalists, who are passionate about novel drug development to fulfill unmet medical needs worldwide. Our pipeline is composed of clinical stage drug candidates with first- ...
    With subsidiaries in Shanghai, Hangzhou and Beijing, Inmagene strives to be the leading company in immunology-related therapeutic areas in China. The company has been founded by a group of entrepreneurs, including clinicians, scientists and former venture capitalists, who are passionate about novel drug development to fulfill unmet medical needs worldwide. Our pipeline is composed of clinical stage drug candidates with first- or best-in-class potentials licensed from global partners. Inmagene has also established the capabilities to conduct innovative research and pre-clinical development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Inmagene BiopharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    12526 High Bluff Drive, Suite 345, San Diego, CA 92130
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.inmagenebio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/inmagene-biopharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Inmagene Biopharmaceuticals Completes Merger with Ikena Oncology
    Inmagene Biopharmaceuticals Completes Merger with Ikena Oncology

    25 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/25/3121877/0/en/Inmagene-Biopharmaceuticals-Announces-Completion-of-Merger-with-Ikena-Oncology-and-Concurrent-Private-Placement-of-75-Million.html

    GLOBENEWSWIRE
    25 Jul 2025
    Share Share
    Kristin Yarema Named CEO of Merged Ikena-Inmagene Entity
    Kristin Yarema Named CEO of Merged Ikena-Inmagene Entity

    23 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/23/3120280/0/en/Ikena-Oncology-and-Inmagene-Biopharmaceuticals-Announce-Kristin-Yarema-Ph-D-as-Chief-Executive-Officer-of-Merged-Company.html

    GLOBENEWSWIRE
    23 Jul 2025
    Share Share
    Ikena Announces Stockholder Approval of Merger with Inmagene Bio
    Ikena Announces Stockholder Approval of Merger with Inmagene Bio

    15 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/15/3116027/0/en/Ikena-Oncology-Announces-Stockholder-Approval-of-Merger-with-Inmagene-Biopharmaceuticals.html

    GLOBENEWSWIRE
    15 Jul 2025
    Share Share
    Ikena-Inmagene Merger Backed by ISS, Glass Lewis
    Ikena-Inmagene Merger Backed by ISS, Glass Lewis

    11 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/11/3113954/0/en/Ikena-Oncology-Announces-ISS-and-Glass-Lewis-Recommend-Stockholders-Vote-FOR-Proposed-Merger-with-Inmagene-Biopharmaceuticals.html

    GLOBENEWSWIRE
    11 Jul 2025
    Share Share
    Inmagene Doses First Patient in IMG-007 Phase 2b Trial
    Inmagene Doses First Patient in IMG-007 Phase 2b Trial

    01 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/01/3108375/0/en/Inmagene-Doses-First-Patient-in-the-ADAPTIVE-Phase-2b-Trial-of-IMG-007-a-Nondepleting-Anti-OX40-mAb-with-an-Extended-Half-life-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis.html

    GLOBENEWSWIRE
    01 Jul 2025
    Share Share
    Inmagene Reports Phase 2a Results of IMG-007 in Alopecia Areata
    Inmagene Reports Phase 2a Results of IMG-007 in Alopecia Areata

    24 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/24/3067491/0/en/Inmagene-Reports-Topline-Results-from-Phase-2a-Study-of-IMG-007-a-Nondepleting-Anti-OX40-Monoclonal-Antibody-with-an-Extended-Half-life-in-Patients-with-Alopecia-Areata.html

    GLOBENEWSWIRE
    24 Apr 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search